Previous close | 0.1199 |
Open | 0.1200 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.1200 - 0.1599 |
52-week range | 0.0412 - 0.1599 |
Volume | |
Avg. volume | 851,644 |
Market cap | 58.484M |
Beta (5Y monthly) | 1.49 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0100 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program. Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Manage
Richland WA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that it certified three additional clinics to offer Isopet® Precision Radionuclide Therapy (PRT). The three new clinics are The Myhre Equine Clinic, located in Rochester, New Hampshire, the Hopkinton Animal Hospital, located in Weare, New Hampshire and the Indian Creek Veterinary Hospital, located in Fort Wayne, Indiana. The Myhre Clinic will be focused on providing equine tumor therapy and